Revelation Biosciences (REVB) Return on Capital Employed (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Return on Capital Employed of 88.74% for Q4 2025, up 7854.0% year-over-year from 1.12% in Q4 2024, and up 21.82% quarter-over-quarter from 113.5% in Q3 2025.
Revelation Biosciences (REVB) Return on Capital Employed (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Return on Capital Employed for 5 consecutive years, with 88.74% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 7854.0% year-over-year to 88.74%; the TTM figure through Dec 2025 stood at 88.74% (up 7854.0% YoY), while the FY2025 annual figure was 127.68%, down 2140.0% from the prior year.
- Return on Capital Employed grew to 88.74% in Q4 2025 per REVB's latest filing, from 113.5% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 519.3% in Q1 2022 and bottomed at 21927.04% in Q2 2022.
- Historically, Return on Capital Employed has averaged 1491.56% across 5 years, with a median of 157.16% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 2187910 bps in 2023 and fell as far as 67829 bps in 2023.
- Revelation Biosciences' Return on Capital Employed stood at 33.51% in 2021, then sank by 1924 bps to 678.4% in 2022, then soared by 83 bps to 113.15% in 2023, then sank by 48 bps to 167.28% in 2024, then soared by 47 bps to 88.74% in 2025.
- Business Quant data shows REVB's Return on Capital Employed at 88.74% in Q4 2025, 113.5% in Q3 2025, and 260.39% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Revelation Biosciences | 4.14 Mn | -7.36 Mn | - | -104.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104.71% |
| Dec 31, 2025 | -88.74% |
| Sep 30, 2025 | -113.50% |
| Jun 30, 2025 | -260.39% |
| Mar 31, 2025 | -194.17% |
| Dec 31, 2024 | -167.28% |
| Sep 30, 2024 | -157.16% |
| Jun 30, 2024 | -404.35% |
| Mar 31, 2024 | -108.63% |
| Dec 31, 2023 | -113.15% |
| Sep 30, 2023 | -77.60% |
| Jun 30, 2023 | -47.94% |
| Mar 31, 2023 | -158.99% |
| Dec 31, 2022 | -678.40% |
| Sep 30, 2022 | -1,345.04% |
| Jun 30, 2022 | -21,927.04% |
| Mar 31, 2022 | 519.30% |
| Dec 31, 2021 | -33.51% |